Summary

Precision Medicine Market By Technology (Big Data Analytics, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics) By Indication (Oncology, CNS, Immunology, Respiratory diseases, Genetic disorders, Skin diseases, Others) By Application (Diagnostics {Genetic Tests, Biomarker Based Tests, Esoteric Tests} Therapeutics {Inhibitor Drugs, Monoclonal Antibodies, Cell & Gene Therapy, Antiviral & anti-retroviral Drugs, Others) By End-user (Hospitals, Diagnostic Laboratories, Others) Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 ? 2035
The Precision Medicine Market accounted for USD 88.2 billion in 2024 and is expected to reach USD 486.8 billion by 2035, growing at a CAGR of around 16.8% between 2025 and 2035. The arena of precision medicine circles around the customization of health care, or the study of and treatment decisions and products tailored to individual characteristics of each patient. Genetic, environmental, and lifestyle factors are integrated for more accurate diagnosis and more effective therapy. It is a movement away from general protocols of therapy toward data-driven patient care. As technologies like genomics, AI, and bioinformatics are reinventing themselves, they open up new territories for rich, effective, targeted interventions. There is increasing collaboration between technology firms and pharma companies in the healthcare field today. Personalized care is a value-added case in the increased demand for better patient outcomes, hence accelerating adoption. Overall, the prospects for the industry are still highly favorable, given continued innovation as well as backing policy frameworks from governments.
Advancements in Genomics and Biotechnology
Increasing genomic technologies will continue to unveil diseases at a molecular level. This would come very timely for early identification, predictive analysis, and an improved personalized treatment plan. For instance, in a setup with next-generation sequencing, clinicians would gain further insight into the uniqueness of an individual's genetic variations and tailor therapies to meet the specific needs of the patients. Such developments would further enhance outcome efficacy while reducing possible adverse ramifications. Additionally, biotechnology firms are investing noteworthy amounts of resources in gene-based innovations. Such initiatives are strengthening the uptake of precision medicine across multiple therapeutic domains.
High Cost of Implementation
Precision medicine relies on advanced diagnostics, genomic testing, and data analytics, all of which come at an extremely high cost. Such technologies require sophisticated equipment, infrastructure, and highly skilled manpower. For many healthcare setups, especially in developing regions, this required investment acts as a significant impediment. Furthermore, patients might incur heavy out-of-pocket costs on account of scant insurance coverage. In this regard, cost-related issues limit the widespread implementation of precision medicine in clinical practice settings. Ensuring equitable access continues to remain a regulatory issue from the standpoint of policymakers and industry players.
Integration of Artificial Intelligence and Big Data
To discover hidden patterns, artificial intelligence (AI) is being employed to analyze large amounts of genomic and clinical data. This integration enhances the accuracy of diagnosis and predictive design of risk for particular diseases and selection of adequate treatment options. The analytics of big data provide a way for timely decision-making and increased efficiency in research. The development of newer algorithms will widen the application of AI in precision medicine. Some companies are developing AI-driven platforms to ease clinical workflow. The combination of AI and precision medicine could bring a paradigm shift in the healthcare sector.
Segment Analysis
Precision medicine is applied to a variety of fields like oncology, cardiology, neurology, infectious diseases, and rare genetic disorders. Oncology seems to be the first area to witness more targeted cancer therapies. Neurological applications have blossomed with brain mapping in general and genetic analysis in recent trends. Cardiology stands to benefit from personalized risk assessments and interventions. For infectious diseases, precision approaches provide the identification of pathogen strains and patient susceptibility, improving outcomes. Several rare genetic disorders have benefited from personalized research to spark new hope for treatment, as most are incurable. Each application area is experiencing significant growth through significant R&D funds.
End-users in the market are mainly composed of hospitals, diagnostic centers, and research institutions. At the forefront of this adoption are the hospitals that have a relatively closer patient interface and credible clinical data. Diagnostic centers are repositories of any meaningful equipment and capability to perform complex tests for timely information delivery. Research institutes traditionally conduct detailed experiments and case studies involving new medicines or therapies for the particular disease under the watchful eyes of qualified professional investigators. These end-user alliances may often drive new opportunities for integrations. Depending on their activities, every end-user segment is likely to determine the availability and scaling of precision healthcare. Improved investments and partnerships are actively improving the resource bases of end-user operations.
Regional Analysis
North America is the leading region in precision medicine, given its robust healthcare infrastructure as well as research ecosystem. Leading biotech firms and a plethora of top academic institutions have a nonstop capacity to innovate. Government initiatives and grants are aggressively pursuing genomics research and personalized treatment programs in the region. In addition, the existence of an established framework regarding regulatory processes supports progress in targeted therapies for this region. This, coupled with high awareness and adoption among health care providers as well as patients, adds impetus to the market. Collaborations of tech companies would integrate AI into primary clinical practice with healthcare providers. The essence of this case is that the U.S. will continue to be a key contributor to this region in driving research and commercial success.
Competitive Landscape
The precision medicine market is characterized by fierce competition and rapid and changing innovation streams. Key participants in this field are the pharmaceutical giants, the diagnostic companies, and the biotech startups, amongst which advancement in treatment personalization is a race. Companies want to forge strategic alliances, mergers, and acquisitions to widen their boundaries and reach globally. R&D and data analytics have accounted for most competitive advantages. Collaborating with many academic and research institutions is also relevant in driving clinical advancement. The focus is increasingly on integrated solutions for diagnostics; that is, solutions with embedded AI plus therapeutics bundled around them. Customization of products for regional needs is growing into a competitive tool. Future market leaders would be determined by new technological differentiation as well as regulatory agility.
Report Coverage:
By Technology
- Big Data Analytics
- Bioinformatics
- Gene Sequencing
- Drug Discovery
- Companion Diagnostics
By Indication
- Oncology
- CNS
- Immunology
- Respiratory diseases
- Genetic disorders
- Skin diseases
- Others
By Application
- Diagnostics
- Genetic Tests
- Biomarker-Based Tests
- Esoteric Tests
- Therapeutics
- Inhibitor Drugs
- Monoclonal Antibodies
- Cell & Gene Therapy
- Antiviral & anti-retroviral Drugs
- Others
By End-user
- Hospitals
- Diagnostic Laboratories
- Others

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology & Report Coverage
1.1. Definition & Objective
1.2. Market Evaluation & forecast parameter
1.3. Research Methodology
1.4. Data Validation Sources
1.4.1. Secondary Research
1.4.2. Primary Research
2. Market Overview
3. Precision Medicine Market: Market Dynamics
3.1. Executive Summary
3.2. Market Driving Factors
3.2.1. Advances in genomics and biotechnology enabling personalized treatments
3.2.2. Increasing prevalence of chronic diseases requiring tailored therapies
3.2.3. Rising demand for companion diagnostics in oncology
3.3. Key Industry Pitfalls & Challenges
3.3.1. Limited availability of large-scale, high-quality genomic data.
3.3.2. Ethical concerns regarding genetic data privacy and patient consent.
3.3.3. High cost of precision medicine technologies limits accessibility for many patients.
3.4. Market Opportunities
3.4.1. Development of rare disease therapies tailored to individual patients
3.4.2. AI-driven diagnostic tools for personalized health assessments
3.4.3. Wearable health devices that monitor and adjust treatments in real-time
3.5. Porter’s Five Forces Analysis
3.6. PESTLE Analysis
3.7. Regulatory landscape
3.8. Pipeline Analysis
3.9. ESG Scenario
3.10. Competitive landscape
3.10.1. Company Market Share
3.10.2. Market Positioning
3.10.3. Strategy framework
3.10.4. Recent Acquisitions & Mergers
4. Precision Medicine Market , By Technology Segment Analysis
4.1. Overview Dynamics
4.1.1. Market Revenue Share, By Technology, 2025 & 2035
4.1.2. Key Market Trends, Growth Factors, & Opportunities
4.2. Big Data Analytics
4.2.1. Market Revenue Share, By Technology, 2025 & 2035
4.3. Bioinformatics
4.3.1. Market Revenue Share, By Technology, 2025 & 2035
4.4. Gene Sequencing
4.4.1. Market Revenue Share, By Technology, 2025 & 2035
4.5. Drug Discovery
4.5.1. Market Revenue Share, By Technology, 2025 & 2035
4.6. Companion Diagnostics
4.6.1. Market Revenue Share, By Technology, 2025 & 2035
5. Precision Medicine Market, By Indication Segment Analysis
5.1. Overview
5.1.1. Market Revenue Share, By Indication, 2025 & 2035
5.1.2. Key Market Trends, Growth Factors, & Opportunities
5.2. Oncology
5.2.1. Market Size and Forecast, By Indication 2025-2035 (USD Million)
5.3. CNS
5.3.1. Market Size and Forecast, By Indication 2025-2035 (USD Million)
5.4. Immunology
5.4.1. Market Size and Forecast, By Indication 2025-2035 (USD Million)
5.5. Respiratory Diseases
5.5.1. Market Size and Forecast, By Indication 2025-2035 (USD Million)
5.6. Genetic Disorders
5.6.1. Market Size and Forecast, By Indication 2025-2035 (USD Million)
5.7. Skin Diseases
5.7.1. Market Size and Forecast, By Indication 2025-2035 (USD Million)
5.8. Others
5.8.1. Market Size and Forecast, By Indication 2025-2035 (USD Million)
6. Precision Medicine Market, By Application Segment Analysis
6.1. Overview
6.1.1. Market Revenue Share, By Application, 2025 & 2035
6.1.2. Key Market Trends, Growth Factors, & Opportunities
6.2. Diagnostics
6.2.1. Market Size and Forecast, By Application 2025-2035 (USD Million)
6.2.2. Genetic Tests
6.2.2.1. Market Size and Forecast, By Application 2025-2035 (USD Million)
6.2.3. Biomarker Based Tests
6.2.3.1. Market Size and Forecast, By Application 2025-2035 (USD Million)
6.2.4. Esoteric Tests
6.2.4.1. Market Size and Forecast, By Application 2025-2035 (USD Million)
6.3. Therapeutics
6.3.1. Market Size and Forecast, By Application 2025-2035 (USD Million)
6.3.2. Inhibitor Drugs
6.3.2.1. Market Size and Forecast, By Application 2025-2035 (USD Million)
6.3.3. Monoclonal Antibodies
6.3.3.1. Market Size and Forecast, By Application 2025-2035 (USD Million)
6.3.4. Cell & Gene Therapy
6.3.4.1. Market Size and Forecast, By Application 2025-2035 (USD Million)

6.3.5. Antiviral & anti-retroviral Drugs
6.3.5.1. Market Size and Forecast, By Application 2025-2035 (USD Million)
6.3.6. Others
6.3.6.1. Market Size and Forecast, By Application 2025-2035 (USD Million)
7. Precision Medicine Market, By End-user Segment Analysis
7.1. Overview
7.1.1. Market Revenue Share, By End-user, 2025 & 2035
7.1.2. Key Market Trends, Growth Factors, & Opportunities
7.2. Hospitals
7.2.1. Market Size and Forecast, By End-user 2025-2035 (USD Million)
7.3. Diagnostic Laboratories
7.3.1. Market Size and Forecast, By End-user 2025-2035 (USD Million)
7.4. Other
7.4.1. Market Size and Forecast, By End-user 2025-2035 (USD Million)
8. Precision Medicine Market , Region Segment Analysis
8.1. Overview
8.1.1. Global Market Revenue Share, By Region, 2025 & 2035
8.1.2. Global Market Revenue, By Region, 2025-2035 (USD Million)
8.2. North America
8.2.1. North America Market Revenue, By Technology, 2025-2035 (USD Million)
8.2.2. North America Market Revenue, By Indication, 2025-2035
8.2.3. North America Market Revenue, By Application, 2025-2035
8.2.4. North America Market Revenue, By End-user, 2025-2035
8.2.5. North America Market Revenue, By Region, 2025-2035
8.2.6. U.S.
8.2.6.1. U.S. Market Revenue, By Technology, 2025-2035 (USD Million)
8.2.6.2. U.S. Market Revenue, By Indication, 2025-2035
8.2.6.3. U.S. Market Revenue, By Application, 2025-2035
8.2.6.4. U.S. Market Revenue, By End-user, 2025-2035
8.2.6.5. U.S. Market Revenue, By Region, 2025-2035
8.2.7. Canada
8.2.7.1. Canada Market Revenue, By Technology, 2025-2035 (USD Million)
8.2.7.2. Canada Market Revenue, By Indication, 2025-2035
8.2.7.3. Canada Market Revenue, By Application, 2025-2035
8.2.7.4. Canada Market Revenue, By End-user, 2025-2035
8.2.7.5. Canada Market Revenue, By Region, 2025-2035
8.3. Europe
8.3.1. Europe Market Revenue, By Technology, 2025-2035 (USD Million)
8.3.2. Europe Market Revenue, By Indication, 2025-2035
8.3.3. Europe Market Revenue, By Application, 2025-2035
8.3.4. Europe Market Revenue, By End-user, 2025-2035
8.3.5. Europe Market Revenue, By Region, 2025-2035
8.3.6. Germany
8.3.6.1. Germany Market Revenue, By Technology, 2025-2035 (USD Million)
8.3.6.2. Germany Market Revenue, By Indication, 2025-2035
8.3.6.3. Germany Market Revenue, By Application, 2025-2035
8.3.6.4. Germany Market Revenue, By End-user, 2025-2035
8.3.6.5. Germany Market Revenue, By Region, 2025-2035
8.3.7. France
8.3.7.1. France Market Revenue, By Technology, 2025-2035 (USD Million)
8.3.7.2. France Market Revenue, By Indication, 2025-2035
8.3.7.3. France Market Revenue, By Application, 2025-2035
8.3.7.4. France Market Revenue, By End-user, 2025-2035
8.3.7.5. France Market Revenue, By Region, 2025-2035
8.3.8. U.K.
8.3.8.1. U.K. Market Revenue, By Technology, 2025-2035 (USD Million)
8.3.8.2. U.K. Market Revenue, By Indication, 2025-2035
8.3.8.3. U.K. Market Revenue, By Application, 2025-2035
8.3.8.4. U.K. Market Revenue, By End-user, 2025-2035
8.3.8.5. U.K. Market Revenue, By Region, 2025-2035
8.3.9. Italy
8.3.9.1. Italy Market Revenue, By Technology, 2025-2035 (USD Million)
8.3.9.2. Italy Market Revenue, By Indication, 2025-2035
8.3.9.3. Italy Market Revenue, By Application, 2025-2035
8.3.9.4. Italy Market Revenue, By End-user, 2025-2035
8.3.9.5. Italy Market Revenue, By Region, 2025-2035
8.3.10. Spain
8.3.10.1. Spain Market Revenue, By Technology, 2025-2035 (USD Million)
8.3.10.2. Spain Market Revenue, By Indication, 2025-2035
8.3.10.3. Spain Market Revenue, By Application, 2025-2035
8.3.10.4. Spain Market Revenue, By End-user, 2025-2035
8.3.10.5. Spain Market Revenue, By Region, 2025-2035
8.3.11. Rest of Europe
8.3.11.1. Rest of Europe Market Revenue, By Technology, 2025-2035 (USD Million)
8.3.11.2. Rest of Europe Market Revenue, By Indication, 2025-2035
8.3.11.3. Rest of Europe Market Revenue, By Application, 2025-2035
8.3.11.4. Rest of Europe Market Revenue, By End-user, 2025-2035
8.3.11.5. Rest of Europe Market Revenue, By Region, 2025-2035
8.4. Asia Pacific
8.4.1. Asia Pacific Market Revenue, By Technology, 2025-2035 (USD Million)
8.4.2. Asia Pacific Market Revenue, By Indication, 2025-2035
8.4.3. Asia Pacific Market Revenue, By Application, 2025-2035
8.4.4. Asia Pacific Market Revenue, By End-user, 2025-2035
8.4.5. Asia Pacific Market Revenue, By Region, 2025-2035
8.4.6. China
8.4.6.1. China Market Revenue, By Technology, 2025-2035 (USD Million)
8.4.6.2. China Market Revenue, By Indication, 2025-2035
8.4.6.3. China Market Revenue, By Application, 2025-2035
8.4.6.4. China Market Revenue, By End-user, 2025-2035
8.4.6.5. China Market Revenue, By Region, 2025-2035
8.4.7. Japan
8.4.7.1. Japan Market Revenue, By Technology, 2025-2035 (USD Million)
8.4.7.2. Japan Market Revenue, By Indication, 2025-2035
8.4.7.3. Japan Market Revenue, By Application, 2025-2035
8.4.7.4. Japan Market Revenue, By End-user, 2025-2035
8.4.7.5. Japan Market Revenue, By Region, 2025-2035
8.4.8. India
8.4.8.1. India Market Revenue, By Technology, 2025-2035 (USD Million)
8.4.8.2. India Market Revenue, By Indication, 2025-2035
8.4.8.3. India Market Revenue, By Application, 2025-2035
8.4.8.4. India Market Revenue, By End-user, 2025-2035
8.4.8.5. India Market Revenue, By Region, 2025-2035
8.4.9. Australia
8.4.9.1. Australia Market Revenue, By Technology, 2025-2035 (USD Million)
8.4.9.2. Australia Market Revenue, By Indication, 2025-2035
8.4.9.3. Australia Market Revenue, By Application, 2025-2035
8.4.9.4. Australia Market Revenue, By End-user, 2025-2035
8.4.9.5. Australia Market Revenue, By Region, 2025-2035
8.4.10. South Korea
8.4.10.1. South Korea Market Revenue, By Technology, 2025-2035 (USD Million)
8.4.10.2. South Korea Market Revenue, By Indication, 2025-2035
8.4.10.3. South Korea Market Revenue, By Application, 2025-2035
8.4.10.4. South Korea Market Revenue, By End-user, 2025-2035
8.4.10.5. South Korea Market Revenue, By Region, 2025-2035
8.4.11. Singapore
8.4.11.1. Singapore Market Revenue, By Technology, 2025-2035 (USD Million)
8.4.11.2. Singapore Market Revenue, By Indication, 2025-2035
8.4.11.3. Singapore Market Revenue, By Application, 2025-2035
8.4.11.4. Singapore Market Revenue, By End-user, 2025-2035
8.4.11.5. Singapore Market Revenue, By Region, 2025-2035
8.4.12. Rest of Asia Pacific
8.4.12.1. Rest of Asia Pacific Market Revenue, By Technology, 2025-2035 (USD Million)
8.4.12.2. Rest of Asia Pacific Market Revenue, By Indication, 2025-2035
8.4.12.3. Rest of Asia Pacific Market Revenue, By Application, 2025-2035
8.4.12.4. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035
8.4.12.5. Rest of Asia Pacific Market Revenue, By Region, 2025-2035
8.5. Latin America
8.5.1. Latin America Market Revenue, By Technology, 2025-2035 (USD Million)
8.5.2. Latin America Market Revenue, By Indication, 2025-2035
8.5.3. Latin America Market Revenue, By Application, 2025-2035
8.5.4. Latin America Market Revenue, By End-user, 2025-2035
8.5.5. Latin America Market Revenue, By Region, 2025-2035
8.5.6. Brazil
8.5.6.1. Brazil Market Revenue, By Technology, 2025-2035 (USD Million)
8.5.6.2. Brazil Market Revenue, By Indication, 2025-2035
8.5.6.3. Brazil Market Revenue, By Application, 2025-2035
8.5.6.4. Brazil Market Revenue, By End-user, 2025-2035
8.5.6.5. Brazil Market Revenue, By Region, 2025-2035
8.5.7. Mexico
8.5.7.1. Mexico Market Revenue, By Technology, 2025-2035 (USD Million)
8.5.7.2. Mexico Market Revenue, By Indication, 2025-2035
8.5.7.3. Mexico Market Revenue, By Application, 2025-2035
8.5.7.4. Mexico Market Revenue, By End-user, 2025-2035
8.5.7.5. Mexico Market Revenue, By Region, 2025-2035
8.5.8. Argentina
8.5.8.1. Argentina Market Revenue, By Technology, 2025-2035 (USD Million)
8.5.8.2. Argentina Market Revenue, By Indication, 2025-2035
8.5.8.3. Argentina Market Revenue, By Application, 2025-2035
8.5.8.4. Argentina Market Revenue, By End-user, 2025-2035
8.5.8.5. Argentina Market Revenue, By Region, 2025-2035
8.5.9. Rest of Latin America
8.5.9.1. Rest of Latin America Market Revenue, By Technology, 2025-2035 (USD Million)
8.5.9.2. Rest of Latin America Market Revenue, By Indication, 2025-2035
8.5.9.3. Rest of Latin America Market Revenue, By Application, 2025-2035
8.5.9.4. Rest of Latin America Market Revenue, By End-user, 2025-2035
8.5.9.5. Rest of Latin America Market Revenue, By Region, 2025-2035
8.6. MEA
8.6.1. MEA Market Revenue, By Technology, 2025-2035 (USD Million)
8.6.2. MEA Market Revenue, By Indication, 2025-2035
8.6.3. MEA Market Revenue, By Application, 2025-2035
8.6.4. MEA Market Revenue, By End-user, 2025-2035
8.6.5. MEA Market Revenue, By Region, 2025-2035
8.6.6. GCC
8.6.6.1. GCC Market Revenue, By Technology, 2025-2035 (USD Million)
8.6.6.2. GCC Market Revenue, By Indication, 2025-2035
8.6.6.3. GCC Market Revenue, By Application, 2025-2035
8.6.6.4. GCC Market Revenue, By End-user, 2025-2035
8.6.6.5. GCC Market Revenue, By Region, 2025-2035
8.6.7. South Africa
8.6.7.1. South Africa Market Revenue, By Technology, 2025-2035 (USD Million)
8.6.7.2. South Africa Market Revenue, By Indication, 2025-2035
8.6.7.3. South Africa Market Revenue, By Application, 2025-2035
8.6.7.4. South Africa Market Revenue, By End-user, 2025-2035
8.6.7.5. South Africa Market Revenue, By Region, 2025-2035
8.6.8. Rest of Middle-East and Africa
8.6.8.1. Rest of Middle-East and Africa Market Revenue, By Technology, 2025-2035 (USD Million)
8.6.8.2. Rest of Middle-East and Africa Market Revenue, By Indication, 2025-2035
8.6.8.3. Rest of Middle-East and Africa Market Revenue, By Application, 2025-2035
8.6.8.4. Rest of Middle-East and Africa Market Revenue, By End-user, 2025-2035
8.6.8.5. Rest of Middle-East and Africa Market Revenue, By Region, 2025-2035
9. Company Profiles
9.1. Abbott Laboratories, Inc
9.1.1. Business Overview
9.1.2. Financial Performance
9.1.3. Product/Service Offerings
9.1.4. Strategies & recent developments
9.1.5. SWOT Analysis
9.2. Abbvie, Inc.
9.2.1. Business Overview
9.2.2. Financial Performance
9.2.3. Product/Service Offerings
9.2.4. Strategies & recent developments
9.2.5. SWOT Analysis
9.3. AstraZeneca plc
9.3.1. Business Overview
9.3.2. Financial Performance
9.3.3. Product/Service Offerings
9.3.4. Strategies & recent developments
9.3.5. SWOT Analysis
9.4. bioMerieux SA
9.4.1. Business Overview
9.4.2. Financial Performance
9.4.3. Product/Service Offerings
9.4.4. Strategies & recent developments
9.4.5. SWOT Analysis
9.5. Bristol-Myers Squibb Company
9.5.1. Business Overview
9.5.2. Financial Performance
9.5.3. Product/Service Offerings
9.5.4. Strategies & recent developments
9.5.5. SWOT Analysis
9.6. Cepheid (Danaher Corporation)
9.6.1. Business Overview
9.6.2. Financial Performance
9.6.3. Product/Service Offerings
9.6.4. Strategies & recent developments
9.6.5. SWOT Analysis
9.7. Eli Lilly & Company
9.7.1. Business Overview
9.7.2. Financial Performance
9.7.3. Product/Service Offerings
9.7.4. Strategies & recent developments
9.7.5. SWOT Analysis
9.8. F. Hoffmann-La Roche
9.8.1. Business Overview
9.8.2. Financial Performance
9.8.3. Product/Service Offerings
9.8.4. Strategies & recent developments
9.8.5. SWOT Analysis
9.9. GlaxoSmithKline plc
9.9.1. Business Overview
9.9.2. Financial Performance
9.9.3. Product/Service Offerings
9.9.4. Strategies & recent developments
9.9.5. SWOT Analysis
9.10. Laboratory Corporation of America Holdings (Covance Inc.)
9.10.1. Business Overview
9.10.2. Financial Performance
9.10.3. Product/Service Offerings
9.10.4. Strategies & recent developments
9.10.5. SWOT Analysis
9.11. Myriad Genetics, Inc.
9.11.1. Business Overview
9.11.2. Financial Performance
9.11.3. Product/Service Offerings
9.11.4. Strategies & recent developments
9.11.5. SWOT Analysis
9.12. Novartis AG
9.12.1. Business Overview
9.12.2. Financial Performance
9.12.3. Product/Service Offerings
9.12.4. Strategies & recent developments
9.12.5. SWOT Analysis
9.13. Pfizer, Inc.
9.13.1. Business Overview
9.13.2. Financial Performance
9.13.3. Product/Service Offerings
9.13.4. Strategies & recent developments
9.13.5. SWOT Analysis
9.14. QIAGEN N.V.
9.14.1. Business Overview
9.14.2. Financial Performance
9.14.3. Product/Service Offerings
9.14.4. Strategies & recent developments
9.14.5. SWOT Analysis
9.15. Quest Diagnostics
9.15.1. Business Overview
9.15.2. Financial Performance
9.15.3. Product/Service Offerings
9.15.4. Strategies & recent developments
9.15.5. SWOT Analysis
9.16. Takeda Pharmaceutical Company Limited
9.16.1. Business Overview
9.16.2. Financial Performance
9.16.3. Product/Service Offerings
9.16.4. Strategies & recent developments
9.16.5. SWOT Analysis
9.17. Thermo Fisher Scientific Inc.
9.17.1. Business Overview
9.17.2. Financial Performance
9.17.3. Product/Service Offerings
9.17.4. Strategies & recent developments
9.17.5. SWOT Analysis
9.18. Vyant Bio, Inc. (Cancer Genetics, Inc.)
9.18.1. Business Overview
9.18.2. Financial Performance
9.18.3. Product/Service Offerings
9.18.4. Strategies & recent developments
9.18.5. SWOT Analysis
9.19. GRAIL
9.19.1. Business Overview
9.19.2. Financial Performance
9.19.3. Product/Service Offerings
9.19.4. Strategies & recent developments
9.19.5. SWOT Analysis
9.20. Guardant Health
9.20.1. Business Overview
9.20.2. Financial Performance
9.20.3. Product/Service Offerings
9.20.4. Strategies & recent developments
9.20.5. SWOT Analysis

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. GLOBAL PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 2. GLOBAL PRECISION MEDICINE MARKET VALUE FOR ACTIVATED CARBON, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 3. GLOBAL PRECISION MEDICINE MARKET VALUE FOR CARBON DERIVATIVES, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 4. GLOBAL PRECISION MEDICINE MARKET VALUE FOR METAL OXIDES, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 5. GLOBAL PRECISION MEDICINE MARKET VALUE FOR CONDUCTIVE POLYMERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 6. GLOBAL PRECISION MEDICINE MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 7. GLOBAL PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 8. GLOBAL PRECISION MEDICINE MARKET VALUE FOR CONSUMER ELECTRONICS, 2025-2035 (USD BILLION)
TABLE 9. GLOBAL PRECISION MEDICINE MARKET VALUE FOR INDUSTRIAL, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 10. GLOBAL PRECISION MEDICINE MARKET VALUE FOR TRANSPORTATION, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 11. GLOBAL PRECISION MEDICINE MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 12. NORTH AMERICA PRECISION MEDICINE MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 13. NORTH AMERICA PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 14. NORTH AMERICA PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 15. U.S PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 16. U.S PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 17. CANADA PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 18. CANADA PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 19. EUROPE PRECISION MEDICINE MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 20. EUROPE PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 21. EUROPE PRECISION MEDICINE MARKET VALUE, END-USERS, 2025-2035 (USD BILLION)
TABLE 22. GERMANY PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 23. GERMANY PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 24. U.K PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 25. U.K PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 26. FRANCE PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 27. FRANCE PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 28. ITALY PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 29. ITALY PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 30. SPAIN PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 31. SPAIN PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 32. ROE PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 33. ROE PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 34. ASIA PACIFIC PRECISION MEDICINE MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 35. ASIA PACIFIC PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 36. ASIA PACIFIC PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 37. CHINA PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 38. CHINA PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 39. INDIA PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 40. INDIA PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 41. JAPAN PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 42. JAPAN PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 43. REST OF APAC PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 44. REST OF APAC PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 45. REST OF WORLD PRECISION MEDICINE MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 46. REST OF WORLD PRECISION MEDICINE MARKET VALUE, BY END-USERS, 2025-2035 (USD BILLION)
TABLE 47. CABOT(NORIT): FINANCIALS
TABLE 48. CABOT(NORIT): PRODUCTS & SERVICES
TABLE 49. CABOT(NORIT): RECENT DEVELOPMENTS
TABLE 50. KURARY CO. LTD: FINANCIALS
TABLE 51. KURARY CO. LTD: PRODUCTS & SERVICES
TABLE 52. KURARY CO. LTD: RECENT DEVELOPMENTS
TABLE 53. BAYER MATERIALSCIENCE AG: FINANCIALS
TABLE 54. BAYER MATERIALSCIENCE AG: PRODUCTS & SERVICES
TABLE 55. BAYER MATERIALSCIENCE AG: RECENT DEVELOPMENTS
TABLE 56. CALGON CARBON CORPORATION: FINANCIALS
TABLE 57. CALGON CARBON CORPORATION: PRODUCTS & SERVICES
TABLE 58. CALGON CARBON CORPORATION: RECENT DEVELOPMENTS
TABLE 59. CARBON NT&F: FINANCIALS
TABLE 60. CARBON NT&F: PRODUCTS & SERVICES
TABLE 61. CARBON NT&F: RECENT DEVELOPMENTS
TABLE 62. SHENZHEN NTP: FINANCIALS
TABLE 63. SHENZHEN NTP: PRODUCTS & SERVICES
TABLE 64. SHENZHEN NTP: RECENT DEVELOPMENTS
TABLE 65. CECA SA: FINANCIALS
TABLE 66. CECA SA: PRODUCTS & SERVICES
TABLE 67. CECA SA: RECENT DEVELOPMENTS
TABLE 68. CNANO TECHNOLOGY: FINANCIALS
TABLE 69. CNANO TECHNOLOGY: PRODUCTS & SERVICES
TABLE 70. CNANO TECHNOLOGY: RECENT DEVELOPMENTS
TABLE 71. DONAU CHEMIE GROUP: FINANCIALS
TABLE 72. DONAU CHEMIE GROUP: PRODUCTS & SERVICES
TABLE 73. DONAU CHEMIE GROUP: RECENT DEVELOPMENTS
TABLE 74. SHOWA DENKO: FINANCIALS
TABLE 75. SHOWA DENKO: PRODUCTS & SERVICES
TABLE 76. SHOWA DENKO: RECENT DEVELOPMENTS